Analysis Tools|
Allele Symbol Allele Name Allele ID |
Tg(Msmb-TAg)183-2Xuan transgene insertion 183-2, JW Xuan MGI:2448148 |
||||||||||||
| Summary |
2 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• 33% incidence of carcinoma, which was distributed throughout all age groups, with no moderately differentiated prostate cancer
|
|
• rapid and uncontrolled tumor development in late age groups, compared to the steadily prolonged cancer development seen in Msmbtm1Xuan mutant mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
 |
• moderately differentiated adenocarcinoma (prostate cancer) was detected by 16-19 weeks of age
• well-differentiated prostate cancer started by 24 weeks of age, mostly in the ventral and dorsolateral prostate lobes (not in the coagulation gland or seminal vesicles) and was detected in 13% of transgenic mice and by 32 weeks or later, prostate cancer was detected in 40% of mice
• poorly differentiated prostate cancer started as early as 16 weeks of age and 8/10 poorly differentiated prostate cancers showed large visible tumors
• 2/3 of castrated mice showed visible, fair-sized carcinoma one month after castration, while 1/3 showed high grade prostatic intraepithelial neoplasia
|
|
|
• some mice exhibited low grade prostatic intraepithelial neoplasia at age 12-19 weeks, then gradually decreased to being unidentifiable at or after 28 weeks of age and some mice exhibited high grade prostatic intraepithelial neoplasia from 12-19 weeks
|
|
• metastatic cells of prostatic origin were found in the lymph nodes with the lymph node cortex replaced with undifferentiated epithelial cells
|
|
|
• detected prostate hyperplasia by 10 weeks of age, with a few mice showing an unexpected appearance of hyperplasia at 16 to 32 weeks of age
|
|
|
• moderately differentiated adenocarcinoma (prostate cancer) was detected by 16-19 weeks of age
• well-differentiated prostate cancer started by 24 weeks of age, mostly in the ventral and dorsolateral prostate lobes (not in the coagulation gland or seminal vesicles) and was detected in 13% of transgenic mice and by 32 weeks or later, prostate cancer was detected in 40% of mice
• poorly differentiated prostate cancer started as early as 16 weeks of age and 8/10 poorly differentiated prostate cancers showed large visible tumors
• 2/3 of castrated mice showed visible, fair-sized carcinoma one month after castration, while 1/3 showed high grade prostatic intraepithelial neoplasia
|
|
|
• some mice exhibited low grade prostatic intraepithelial neoplasia at age 12-19 weeks, then gradually decreased to being unidentifiable at or after 28 weeks of age and some mice exhibited high grade prostatic intraepithelial neoplasia from 12-19 weeks
|
|
• transgenic mice with visible prostate tumors had enlarged renal lymph nodes
|
|
|
• detected prostate hyperplasia by 10 weeks of age, with a few mice showing an unexpected appearance of hyperplasia at 16 to 32 weeks of age
|
|
|
• moderately differentiated adenocarcinoma (prostate cancer) was detected by 16-19 weeks of age
• well-differentiated prostate cancer started by 24 weeks of age, mostly in the ventral and dorsolateral prostate lobes (not in the coagulation gland or seminal vesicles) and was detected in 13% of transgenic mice and by 32 weeks or later, prostate cancer was detected in 40% of mice
• poorly differentiated prostate cancer started as early as 16 weeks of age and 8/10 poorly differentiated prostate cancers showed large visible tumors
• 2/3 of castrated mice showed visible, fair-sized carcinoma one month after castration, while 1/3 showed high grade prostatic intraepithelial neoplasia
|
|
|
• some mice exhibited low grade prostatic intraepithelial neoplasia at age 12-19 weeks, then gradually decreased to being unidentifiable at or after 28 weeks of age and some mice exhibited high grade prostatic intraepithelial neoplasia from 12-19 weeks
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| prostate cancer | DOID:10283 |
OMIM:176807 OMIM:300147 OMIM:300704 OMIM:601518 OMIM:602759 OMIM:608656 OMIM:608658 OMIM:609299 OMIM:609558 OMIM:610321 OMIM:610997 OMIM:611100 OMIM:611868 OMIM:611928 OMIM:611955 OMIM:611958 OMIM:611959 |
J:80313 | |
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 11/05/2024 MGI 6.24 |
|
|
|
||
